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correspondence
CNS lymphoma
To th e  E d ito r :  Lachance et a l1 report results in 10 patients 
treated according to a standardized protocol with standard-dose 
cyclophosphamide, doxorubicin, vincristine, and prednisone 
(CHOP). Several issues can be raised regarding this report. 
First, patients with neuroradiographically and pathologically 
documented parenchymal prim ary CNS lymphoma (PCNSL) 
were evaluated for systemic lymphoma. I am unaware of any 
studies tha t demonstrate brain parenchymal métastasés result­
ing from systemic non-Hodgkin’s lymphoma (NHL). Rather, the 
common pattern  of CNS métastasés of systemic NHL is either 
epidural spinal cord compression or lymphomatous meningitis 
(LM).2'6 Therefore, I would subm it th a t a systemic extent of 
d ise a se  e v a lu a t io n  is b o th  u n n e c e s s a ry  and  i r re le v a n t .  
However, by contrast, careful staging of the CNS is quite rele­
van t to trea tm en t p lanning of PCNSL. CNS staging should 
include slit-lamp examination for possible uveal or vitreous eye 
disease, CSF cytology for possible lymphomatous meningitis, 
and  sp ine  im ag in g  (e i th e r  C T -m yelography  or co n tra s t-  
enhanced spine MRI) for possible drop métastasés. Evidence of 
eye disease necessitates orbital radiotherapy. Positive CSF 
cytology or a neuroradiographic pa tte rn  compatible with LM 
necessitates either craniospinal irradiation  or involved-field 
radiotherapy and intra-CSF chemotherapy. Spinal drop métas­
tasés necessitate a treatm ent similar to th a t described for lym­
phomatous meningitis. In the paper by Lachance et al,1 CNS 
staging of patients with PCNSL appears not to have been uni­
formly performed and may partially account for the modest out­
comes reported.
Second, I am unaware of any compelling data to recommend 
craniospinal irradiation in the adjuvant treatm ent of PCNSL. 
R ad ia ting  the  en tire  neurax is  is associated w ith m oderate 
patient morbidity, often resulting in myelosuppression and radi­
ation enteritis, and may, in addition, compromise the ability to 
give chem otherapy due to rad ia tion -induced  bone marrow 
injury. Whole-brain or involved-field radiotherapy combined 
with ad juvant chem otherapy not only obviates the need for 
craniospinal irradiation but also, as discussed below, results in 
superior survival outcomes.2,3,5'9
Third, although CHOP is effective for systemic NHL, it 
might be expected to be less than effective for PCNSL. Of the 
four active agents in the CHOP protocol, only cyclophosphamide 
has dem onstrated substantial activity against primary brain 
tumors—at, however, doses two to three times greater than that 
employed in CHOP .10 Vincristine and prednisone likely have 
activity against systemic lymphomas but probably contribute 
little to regimens directed against CNS tumors. Considerably 
greater activity and correspondingly improved patient survival 
have been reported with drug regimens demonstrating substan­
tia l brain  parenchym al pene tra tion , such as the  high-dose
methotrexate/intra-methotrexate/radiotherapy/high-dose ara-C
regimen described by DeAngelis et al, the CHAD regimen (cis- 
p la tin /h ig h -d o se  a ra -C /d ex am eth ason e) described  by Mc­
Laughlin et al, the radiotherapy plus hydroxyurea followed by 
PCV (procarbazine/CCNU/vincristine) regimen described by 
Chamberlain and Levin, the high-dose methotrexate regimen of 
G la sse t  al, and  b lo o d -b ra in -b a rr ie r  d is ru p tio n  reg im ens 
described by Neuwelt et a l .7"11 These regimens, which may be 
equa lly  efficacious a g a in s t  PCN SL in im m unocom peten t 
patients, result in 40- to 48-month median survival, a substan­
tia l im provem ent over the  whole-brain plus CHOP regimen 
reported by Lachance et al.1
I believe the ne uro-oncology literature strongly supports the 
inclusion of adjuvant chemotherapy to involved-field radiothera­
py in the treatm ent of immunocompetent patients with PCNSL; 
however, chemotherapy regimens superior to CHOP are avail­
able and more rationally utilized against these tumors.
Marc C. Chamberlain, MD
La Jolla, CA
R e p ly  f ro m  th e  A u th o r :  We are in agreem ent w ith Dr. 
Chamberlain. We certainly do not advocate CHOP as the ideal 
regimen for primary CNS lymphoma. In fact, our results argue 
against its use, and we closed this study early because of the 
high recurrence rate. The point of our paper was the unusual 
pattern  of intracerebral recurrence a t apparently uninvolved 
sites after an initial response at the primary sites.
S. Clifford Schold, Jr., MD
Dallas, TX
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Cabergoline in Parkinson’s disease
To th e  E d ito r: Lieberman et al1 and Lera et al2 concluded that 
cabergoline can provide continuous dopaminergic stimulation in 
patients with Parkinson's disease (PD) when taken orally once a 
day. It is possible, however, that the improvement after cabergo­
line—for example, the decrease in “off” time in both studies—is 
partly due to a peak effect in the morning hours following intake 
of cabergoline.
Four PD patients participating in an open study of cabergoline 
in PD with motor fluctuations took cabergoline (mean dose, 8 ± 
1.9 mg) at 8 a m  for 1 week and at 2 pm for another week. All other 
medications remained the same. These patients kept diaries of 
their motor function for 2 weeks from 8 a m  until 11 PM by record­
ing at half-hour intervals whether they were “on” or “off.” We 
used paired t tests to compare 28 days on which cabergoline was 
taken at 8 AM with 28 days when the daily intake was at 2 PM.
I t  appears th a t the tim ing of cabergoline adm inistration 
influences the course throughout the day of hours "off' (figure). 
When cabergoline was taken at 8 a m  the number of hours “off5 
between 8 AM and 2 pm was 1.4 ± 1.0 hours, fewer than the 2.3 ± 
1.0 hours recorded when cabergoline was taken at 2 PM (p =
0.000). Intake at 2 pm resulted in 1.4 ± 0.9 hours “off* between 2 
PM and 7 pm,  fewer than the 2.0 ± 1.1 hours after intake a t 8 AM 
(p = 0.024). The results in the evening hours between 7 PM and
11 PM did not differ significantly according to the time of caber-
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Figure. When cabergoline is administered at 8 a m  (08h), there 
are fewer hours “off* in the morning than when cabergoline is 
taken at 2 PM (14h). When taken at 2 p m , there are fewer hours 
“o ff * in the afternoon than when cabergoline is taken at 8 AM.
This suggests that there is a peak-dose effect o f cabergoline that 
does not last throughout the entire day.
goline administration: at 8 a m ,  “off1 = 1.3 ± 0.9 hours; at 2 pm, 
“off’ = 1.4 ± 0.8 hours (p = 0.74),
Although the number of subjects is too small to warrant any 
definite conclusion, our results do suggest a peak-dose effect of 
cabergoline during the first 5 to 6 hours after administration. 
This time course matches the course of daily plasma levels of 
cabergoline (see figure, Lera et al2), showing higher levels 5 to 6 
hours after cabergoline intake, especially a t the higher dose of 7 
mg as taken by our patients.
Lera et al2 reported an improvement of early morning akine­
sia in all patients, and early morning dystonia practically disap­
peared. This clearly indicates that cabergoline does exert a long- 
acting dopaminergic effect after the first 5 to 6 hours, but as 
matters stand at present, further studies will have to be carried 
out before one can conclude that the easiest way to administer 
cabergoline (ie, once a day) is also the most effective therapeutic 
strategy. Despite cabergoline’s long-acting properties, adminis­
tration two or three times a day may prove more beneficial than 
once daily because the former strategy also implies the benefi­
cial effects of two or three times a peak-dose effect, especially in 
higher doses of cabergoline.
M. W.LM . Horst ink 
H J.C . Berger
C.J. W. van de Vlasakker
Nijmegen, The Netherlands
Reply from  th e  Author: The study by Horstink et al is interest­
ing although limited in size. Cabergoline may be more effective in 
some patients when given in two divided doses. In the majority of 
patients in open studies, the convenience of a once-daily dose out­
weighs the relatively minor benefit of two divided doses.
Abraham  Lieber man, MD
Phoenix, A Z
Reply from  th e  Authors: The observation of Horstink et al is 
clearly of great practical interest in the attempt to achieve the 
best possible therapeutic efficacy for cabergoline. A similar situa­
tion occurred when pergolide was first experimented with in 
parkinsonian patients and led to the now-common 3 doses/d 
application of this dopaminergic agonist. We have observed a 
sustained motor improvement even after 3 days of stopping 
cabergoline, and the drug is generally effective in many patients 
at doses lower than 7 mg/d. We do not believe, therefore, that the 
observation of Horstink et al is against the idea that cabergoline 
provides a relatively continuous dopaminergic stimulation. In
fact, there is a major problem with their data in that the obser­
vation is apparently based on patients’ diaries rather than direct 
observation by the investigators. Given the relatively  small 
changes in the time “off’ (less than 60 minutes) and the well- 
known lack of reliability of patients’ self-assessments, the possi­
bility of a placebo-induced effect should be strongly considered.
J.A. Obeso, MD 
G. Lera, MD
Pamplona, Spain
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Beethoven’s illness
To th e  E d ito r: I read Drake’s article on Beethoven’s possible 
neurosarcoidosis1 with much interest and would like to add the 
following: “Beethoven was an artist, but a m an as well,” So 
wrote Franz Grillparzer in his funeral oration for the composer.2 
Beethoven’s music is immortal, but he was endowed with ta l­
ents and limitations, with strengths and weaknesses of charac­
ter .2 He fell in love often and he had several affairs with “well­
born, well-bred women. . . . Although Beethoven frequently  
regretted not having a wife, he sensed tha t a stable domestic life 
would have ill-suited his artistic temperament.”2
Nettl3 gave a thorough and complete account of Beethoven 
and his relation to the medical profession. In addition to constant 
contact with his friend Professor Franz Wegeler, Beethoven also 
consulted J.H. Crevelt in Bonn, Johann Nepomuk Hunczovsky 
(Mozart’s doctor), Dr. Ludwig Freiherr von Turkheim in Vienna, 
Dr. Johann Peter Frank (with whom he consulted about his deaf­
ness and diarrhea), and Dr, Gerhardt von Vering, who was Staff 
Surgeon in Charge to Emperor Joseph II.
Beethoven wrote to Wegeler: “For several days Vering has 
been applying, to both my arms, vesicants consisting of some 
bark or other—I expect you know what I mean. This is a most 
unpleasant form of treatment, because it always robs me of the 
use of my arms for several days—until the bark has taken prop­
er effect—and is extremely painful to boot. But I m ust admit 
th a t  the  buzzing and  ringing in my ears is now som ew hat 
fainter, particularly in my left ear. Although so far my hearing 
has not improved in any way . . . my bowels are now on the 
mend; when I have taken the lukewarm baths for several days, I 
feel quite well for a  week. . . . Sometimes I take a tonic for my 
stomach. . . .  I am now also following your advice and applying 
herbs to my belly. . . . Vering won’t hear of my taking shower- 
baths.” Beethoven also had  the hab it of drinking  enormous 
quantities of water, and poured a jug of cold water over his head 
without drying himself! He felt “hot” at work. He also consulted 
Johann  Adam Schmidt, Johann  M alfatti, Rohrich, A ndreas 
Wawruch, Andreas Bertolini, Jakob Staudenheim (who sent him 
for balneotherapy in Karlsbad), and Smettana.
Davies4 proposed th a t  the composer suffered from immuno- 
poietic complications of his inflammatory bowel disease along 
with alcoholic cirrhosis of the liver and ototoxicity of the chin- 
chona bark  (antipyretic). Liston et al5 suggested other causes 
of his deafness: syphilis, otosclerosis, and P ag e t’s d isease  
(remember the thickness of the vault of his skull and his huge 
forehead!).
Beethoven’s deafness had no effect on his musical productivi­
ty and creativity ,6,6 but psychologically he became depressed, 
unhappy, and isolated. Between bouts of depression, he com­
posed some of his finest material,6 and he wrote: “Let your deaf­
ness no longer remain a secret—not even in a r t .”6
Like other deaf composers—Rossini and Sibelius—Beethoven
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